Clinical features of herpes simplex virus reactivation after microvascular decompression for trigeminal neuralgia: Experience of 200 patients and a literature review

Asami Kikuchi1, Sumiko Ishizaki2, Suguru Yokosako1, Hidetoshi Kasuya3, Yuichi Kubota1

Departments of 1Neurosurgery and 2Dermatology, Tokyo Women's Medical University Adachi Medical Center, 3Department of Neurosurgery, Neuro Machida Clinic, Tokyo, Japan.

E-mail: *Asami Kikuchi - kikuchi.asami@twmu.ac.jp; Sumiko Ishizaki - ishizaki.sumiko@twmu.ac.jp; Suguru Yokosako - yokosako.suguru@twmu.ac.jp; Hidetoshi Kasuya - 3z7n3v@bam.biglobe.ne.jp; Yuichi Kubota - kubota.yuichi@twmu.ac.jp

ABSTRACT

Background: Herpes simplex virus (HSV) reactivation occasionally develops in the early postoperative period after microvascular decompression (MVD) for trigeminal neuralgia (TN). Therefore, the present study investigated the clinical features of this phenomenon.

Methods: The study cohort comprised 200 patients with 125 women aged between 17 and 90 years (median age, 66 years) who underwent MVD for TN between January 2010 and December 2020. Characteristics were compared between patients with and without HSV reactivation and clinical features were analyzed.

Results: Twenty patients had HSV reactivation: herpes labialis in 18 and herpes zoster (final diagnosis) in 2. A multivariate analysis revealed independent correlations between postoperative HSV reactivation and a previous history of herpes labialis (odds ratios [OR]: 6.32, P = 0.0003) and reoperation for recurrent or persistent pain (OR: 5.06, P = 0.0211). No significant differences were observed in pain relief, postoperative facial numbness, or Barrow Neurological Institute Pain Intensity/Facial Numbness Scores in the past follow-up between patients with and without HSV reactivation. HSV reactivation manifested at a median of the 4th postoperative day (1–10 days) and its location was not related to the preoperative distribution of facial pain. All patients were treated with local acyclovir and were completely cured within 1–2 weeks.

Conclusion: HSV reactivation occurred in 10% of patients after MVD including 1% of herpes zoster. A previous history of herpes labialis and reoperation was identified as risk factors for reactivation. Symptoms were completely cured by antiviral drugs within 1–2 weeks. It is important to note that cases of herpes zoster may be confused with cases of HSV after MVD.

Keywords: Herpes simplex, Herpes zoster, Microvascular decompression, Reactivation, Trigeminal neuralgia

INTRODUCTION

Burdick et al.[7] initially reported herpes simplex following decompression surgery for trigeminal neuralgia (TN), with approximately one-third of patients developing herpes simplex on skin supplied by the manipulated nerve. Pazin and Ho[11,19,20], who developed and established the microvascular decompression (MVD) procedure, investigated herpes simplex virus (HSV) reactivation after MVD of the trigeminal nerve in 1978. Reactivation was detected in 28 out
of 56 patients, and a history of recurrent herpes labialis was associated with an increased risk of reactivation after surgery. These findings indicated that a minimal stimulation or inapparent trauma to the trigeminal sensory root was sufficient to activate latent HSV. HSV reactivation has since been identified as one of the postoperative complications that develop after various lesioning procedures, including glycerol injection, percutaneous balloon compression, surgical and radiofrequency rhizotomy, and MVD. Although only HSV reactivation has been detected, the symptoms of herpes zoster may be included in the literature. These clinical features have not yet been clarified in sufficient detail. We, herein, report our experience of 200 consecutive patients who underwent MVD for TN derived from prospectively collected data and outcome measures based on follow-up notes and responses to a mailed questionnaire. The incidence and features of HSV reactivation in the literature are also reviewed.

MATERIALS AND METHODS

Between January 2010 and December 2020, 293 consecutive patients with TN underwent MVD in the Tokyo Women’s Medical University Medical Center East (currently Adachi Medical Center). Figure 1 shows a flowchart of case selection for the retrospective analysis. The study cohort included 200 patients. All clinical and surgical data were extracted from a prospectively maintained computer database, while the assessment of outcome measures was based on follow-up notes and responses to a mailed questionnaire. The research protocol was approved by the Institutional Review Board of Tokyo Women’s Medical University (No. 2741).

All surgeries were performed by the senior author (H.K.) after patients had provided their informed consent, as previously reported. After surgery, patients were generally observed overnight in Neuro-ICU. An initial assessment of pain relief was conducted and head CT was routinely performed the day after the intervention. Since we detected herpes labialis in patients after MVD for TN in 2009, we, carefully, examined patients for any signs or symptoms of herpes labialis and facial/oral vesicles. Since patients were not always aware of these symptoms by themselves, they were carefully monitored and we have been making a prospectively collected database. Patients were discharged approximately 1 week after surgery and the first follow-up was conducted within 1–2 weeks at an outpatient clinic.

Figure 1: A flowchart of case selection for this retrospective analysis. HV: herpes virus, MVD: microvascular decompression, TN: trigeminal neuralgia.
Pain relief and facial numbness were assessed according to the Barrow Neurological Institute (BNI) Pain Intensity and Facial Numbness Score.[21]

Statistical analysis

Subgroup comparisons were performed using Fisher's exact test and the Wilcoxon signed-rank sum test for categorical and continuous variables, respectively. The level of significance was defined as \( P < 0.05 \). Factors demonstrating significant or borderline \( (P < 0.1) \) relationships with the variable of interest (“postoperative HSV reactivation”) in the univariate analysis were included in multivariate modeling using logistic regression and odds ratios (OR) and their 95% confidence intervals (CI). All calculations were performed using the free software R: a language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

The characteristics of patients in the study cohort are shown in Table 1. Briefly, 186 (93%) patients underwent primary MVD for TN, and 14 (7%) were reoperated for recurrent or persistent pain after the initial intervention either in our center or elsewhere. There were 125 (63%) women and 75 (38%) men aged between 17 and 90 years (median age, 66 years). Pain was localized solely within the areas of the ophthalmic (V1), maxillary (V2), and mandibular (V3) divisions of the trigeminal nerve in 6 (3%), 52 (26%), and 48 patients (24%), respectively. The remaining patients developed pain in more than two divisions. Forty-two (21%) patients had a previous history of herpes labialis. The superior cerebellar artery was the most commonly affected vessel (in 106 patients [53%]) and facial numbness was the most common complication (in 31 patients [16%]). Immediate complete pain relief was achieved in 181 patients (91%). Symptoms recurred in 30 (15%) patients at a median follow-up of 58 months. BNI pain intensity and facial numbness scores[20] in the last follow-up were I/II in 168 (84%) and 192 patients (95%), respectively.

Among 200 patients with TN after MVD, the reactivation of HSV was detected in 20 patients: 18 with herpes labialis, one with face, oral, and tongue vesicles, and one with face vesicles. Dermatologists finally diagnosed the latter two as herpes zoster [Table 2], one of which was confirmed serologically. Immunoserological testing showed a positive result for varicella-zoster virus (CF: Complement fixation) 8× (normal: 0–3×).

Comparisons of patients with and without a positive diagnosis of HV reactivation during the early postoperative period after MVD revealed significantly higher rates of reoperation (20% vs. 6%, \( P = 0.0380 \)) and a previous history of herpes labialis (55% vs. 17%, \( P = 0.0004 \)). In addition, the absence of the intraoperatively identified offending vessel was more frequently noted (\( P = 0.0653 \)) in patients with postoperative HSV reactivation. An analysis of these three predictive factors in the multivariate model revealed independent correlations between HSV reactivation and a previous history of herpes labialis (OR: 6.32, 95% CI: 2.34–17.08, \( P = 0.0003 \)) and reoperation (OR: 5.06, 95% CI: 1.28–20.06, \( P = 0.0211 \)). None of the other factors evaluated significantly differed between the subgroups. Furthermore, no significant differences were observed in pain relief, postoperative facial numbness, or BNI Pain Intensity/Facial Numbness Scores at the last follow-up between patients with and without HSV reactivation [Table 1].

Symptoms appeared at a median of the 4th postoperative day (1–10 days). One patient exhibited symptoms on the opposite site, whereas ten patients developed herpes labialis elsewhere to the division of neuralgia [Table 2]. Encephalitis was not detected in any patients. All patients were treated by the oral administration or local application of acyclovir and were completely cured within 1–2 weeks. In two cases of herpes zoster, neither subsequently developed post zoster neuralgia.

DISCUSSION

HSV reactivation occurred in 10% of patients after MVD for TN, including 1% with herpes zoster, and a herpes history of herpes labialis and reoperation was identified as risk factors for reactivation. The most common symptoms are herpes labialis, with 3–5 vesicles on the vermilion border of the lip preceded by pain, while the incidence of herpes simplex encephalitis following neurosurgery due to virus reactivation is very low.[17] Most patients may simply be monitored, particularly if they are not immunocompromised, and the risk of developing severe disease or complications is low.[24]

When HV reactivation occurs in patients with atopic dermatitis or those in an immunocompromised state, it may have a severe clinical presentation called Kaposi’s varicelliform eruption, for which the head, neck, and trunk are the predominant sites. Complications include keratoconjunctivitis, meningitis, and encephalitis.[1]

Patients in the present study were treated with systemic and local antivirus drugs and herpes labialis was completely cured within 1–2 weeks without deterioration. Oral acyclovir reduces the time to the loss of crusts from approximately 7 to 8 days, but does not alter the time required for complete healing.[23]

Herpes zoster is included in HSV reactivation after MVD. Cushing,[10] initially, reported herpes zoster on the face at the area of anesthesia in 1905 and it was accompanied by a concomitant lesion on the lower sacral posterior root ganglia in two out of 20 patients following the removal of the Gasserian ganglion for TN. Carton and Kilbourne[4] detected herpes simplex in 16 out of 17 patients after trigeminal sensory root section for TN. Based on the location of lesions, two cases were
suspected to be herpes zoster. Since Cushing reported herpes zoster reactivation after trigeminal nerve surgery, difficulties are associated with differentiating between herpes simplex and zoster.\(^5\) Herpes zoster has not been reported in many studies, even those with a large number of patients \([Table 3]\). Any facial and oral vesicles other than on the vermilion border suggest herpes zoster, the characteristics and clinical course of which differ from those of herpes simplex. Simms and Dunn\(^{[22]}\) reported that a patient developed herpes zoster of the maxillary division of the trigeminal nerve after MVD. This may result in severe ocular complications, including blindness. In cases, in which an unusual type of herpes labialis was

---

**Table 1:** Characteristics of 200 TN patients who underwent MVD.

| Evaluated characteristics                       | Total | HSV reactivation during the early postoperative period after MVD for TN | P-value |
|-------------------------------------------------|-------|------------------------------------------------------------------------|---------|
|                                                 |       | Positive\(^*\) | Negative |        |
| Number of patients                              | 200   | 20           | 180      | NA      |
| Type of surgery                                 |       |              |          |         |
| Primary                                         | 186   | 16           | 170      | 0.0380  |
| Reoperation for recurrent or persistent pain    | 14    | 4            | 10       |         |
| Median age in years (range)                     | 66 (17–90) | 64 (47–84) | 65 (17–90) | 0.6912  |
| Sex                                             |       |              |          |         |
| Women                                           | 125   | 15           | 110      |         |
| Men                                             | 75    | 5            | 70       |         |
| Facial pain side                                |       |              |          |         |
| Right                                           | 129   | 15           | 114      |         |
| Left                                            | 71    | 5            | 66       |         |
| Facial pain distribution                        |       |              |          |         |
| V1                                              | 6     | 0            | 6        | 1.0000  |
| V2                                              | 52    | 6            | 46       | 0.7883  |
| V3                                              | 48    | 5            | 43       | 1.0000  |
| V1/V2                                           | 32    | 3            | 29       | 1.0000  |
| V2/V3                                           | 46    | 5            | 41       | 0.7841  |
| V1/V2/V3                                        | 16    | 1            | 15       | 1.0000  |
| Previous history of herpes labialis             | 42    | 11           | 31       | 0.0004  |
| Intraoperative findings of offending vessels    |       |              |          |         |
| SCA                                             | 106   | 9            | 97       | 0.4864  |
| AICA                                            | 23    | 3            | 20       | 0.7089  |
| VA                                              | 9     | 0            | 9        | 0.6028  |
| Vein                                            | 52    | 5            | 47       | 1.0000  |
| No offending vessel                             | 10    | 3            | 7        | 0.0653  |
| Postoperative complications                     |       |              |          |         |
| Facial numbness                                 | 31    | 5            | 26       | 0.2060  |
| CSF leakage                                     | 2     | 0            | 2        | 1.0000  |
| Infection                                       | 3     | 0            | 3        | 1.0000  |
| Hearing disturbance                             | 2     | 0            | 2        | 1.0000  |
| Pain outcome after surgery                      |       |              |          |         |
| Immediate complete pain relief                  | 181   | 18           | 163      | 1.0000  |
| Delayed complete pain relief                    | 10    | 0            | 10       | 0.6026  |
| Decreased pain intensity without complete relief| 9     | 2            | 7        | 0.2233  |
| Median length of the follow-up in months (range) | 58 (4–133) | 59 (6–131) | 58 (4–133) | 0.7991  |
| Pain recurrence during the follow-up            | 30    | 3            | 27       | 1.0000  |
| BNI Pain Intensity Score in the past follow-up  |       |              |          |         |
| I/II                                            | 168   | 16           | 152      |         |
| III/IV/V                                       | 32    | 4            | 28       |         |
| BNI Facial Numbness Score in the past follow-up |       |              |          |         |
| I/II                                            | 192   | 19           | 173      |         |
| III/IV                                          | 8     | 1            | 7        |         |

HSV: Herpes simplex virus, MVD: microvascular decompression, TN: trigeminal neuralgia, SCA: superior cerebellar artery, AICA: anterior inferior cerebellar artery, VA: vertebral artery, BNI: Barrow Neurological Institute, NA: not applicable. Bold: Statistically significant values. \(^*\)Including two cases of herpes zoster
| Case number | Age (years) | Sex | Affected side | Affected area | Previous history of herpes labialis | Recurrent surgery | Cause of trigeminal neuralgia | Pain relief | Postoperative facial numbness | Day of clinical manifestation | Affected side | Herpes labialis | Other symptoms possibly caused by herpes zoster | Treatment |
|-------------|-------------|-----|---------------|---------------|-------------------------------------|-----------------|-------------------------------|-------------|-----------------------------|-----------------------------|-------------|---------------|------------------------------------------------|-----------|
| 1           | 70          | F   | Right         | V2            | No                                   | SCA             | Immediate                     | Right       | Upper/Lower                 | 2              | Right       | V2 face oral vesicle | V3 tongue vesicle | Systemic   |
| 2           | 49          | F   | Right         | V3            | No                                   | SCA             | Immediate                     | Yes         | Right                       | 3              | Right       | Systemic       |                      |           |
| 3           | 51          | F   | Right         | V2            | Yes                                  | Teflon granuloma| Immediate                     | Left        | Lower                       | 2              | Left        | Systemic       |                      |           |
| 4           | 47          | F   | Right         | V3            | Yes                                  | Vein            | Immediate                     | Right       | Upper                       | 6              | Right       | Systemic       |                      |           |
| 5           | 54          | M   | Left          | V2V3          | No                                   | SCA             | Incomplete                    | Left        | Upper/Lower                 | 5              | Right       | Systemic       |                      | Local      |
| 6           | 72          | M   | Left          | V2            | No                                   | SCA             | Immediate                     | Left        | Lower                       | 1              | Left        | Systemic       |                      |           |
| 7           | 54          | F   | Right         | V2            | Yes                                  | SCA             | Immediate                     | Right       | Upper/Lower                 | 2              | Right       | Systemic       |                      | Local      |
| 8           | 49          | M   | Right         | V2V3          | Yes                                  | Vein            | Immediate                     | Right       | Upper/Lower                 | 5              | Right       | Systemic       |                      | Local      |
| 9           | 84          | F   | Left          | V1V2          | No                                   | SCA             | Immediate                     | Left        | Upper/Lower                 | 10             | Left        | Local          |                      |           |
| 10          | 64          | F   | Right         | V3            | Yes                                  | SCA             | Immediate                     | Right       | Lower/Lower                 | 3              | Right       | Local          |                      | Local      |
| 11          | 76          | F   | Right         | V1V2V3        | Yes                                  | Teflon granuloma| Immediate                     | Right       | Upper/Lower                 | 6              | Right       | Systemic       |                      | Local      |
| 12          | 71          | F   | Left          | V3            | No                                   | AICA            | Immediate                     | Left        | Upper/Lower                 | 7              | Left        | Systemic       |                      | Local      |
| 13          | 59          | F   | Right         | V2V3          | Yes                                  | Vein            | Immediate                     | Right       | Lower/Lower                 | 3              | Right       | Systemic       |                      | Local      |
| 14          | 73          | F   | Right         | V2V3          | Yes                                  | Vein            | Incomplete                    | Right       | Lower/Lower                 | 6              | Right       | Systemic       |                      | Local      |
| 15          | 62          | F   | Right         | V2V3          | Yes                                  | AICA            | Immediate                     | Right       | Lower/Lower                 | 4              | Right       | V1V2 face vesicle |                      | Local      |
| 16          | 67          | M   | Right         | V1V2          | No                                   | Vein            | Immediate                     | Right       | Upper/Lower                 | 4              | Right       | Local          |                      | Systemic   |
| 17          | 63          | F   | Right         | V1V2          | No                                   | SCA             | Immediate                     | Right       | Upper/Lower                 | 2              | Right       | Systemic       |                      | Systemic   |
| 18          | 83          | M   | Left          | V3            | Yes                                  | AICA            | Immediate                     | Right       | Upper/Lower                 | 4              | Left        | Systemic       |                      | Systemic   |
| 19          | 57          | F   | Right         | V2            | Yes                                  | SCA             | Immediate                     | Right       | Upper/Lower                 | 3              | Right       | Systemic       |                      | Systemic   |
| 20          | 69          | F   | Right         | V2            | No                                   | Teflon granuloma| Immediate                     | Right       | Upper/Lower                 | 7              | Right       | Systemic       |                      | Systemic   |

F: Female, M: Male; V1, V2, and V3: ophthalmic, maxillary, and mandibular divisions of the trigeminal nerve, respectively, SCA: superior cerebellar artery, AICA: anterior inferior cerebellar artery, HSV: herpes simplex virus.
detected, herpes zoster was diagnosed based on the clinical course and subsequent immunological tests. Varicella-zoster virus is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia. Decades later, the virus may reactivate spontaneously or after a number of triggering factors to cause herpes zoster (shingles).[^14] Herpes zoster presents as a unilateral, self-limited dermatomal rash. Antiviral therapy for acute herpes zoster is indicated for patients with nontruncal involvement.[^12] Antiviral agents are effective if promptly commenced. We administered antiviral drugs to patients with herpes simplex and zoster. The careful diagnosis of herpes zoster and administration of antiviral drugs to patients is strongly recommended.

HSV reactivation did not always occur at the area of facial pain or on the side of the manipulation. Since the whole trigeminal root is manipulated in MVD, the area of HSV reactivation is not always the same division of the trigeminal nerve. We, previously, encountered one patient who developed symptoms on the other side of surgery.[^7]

HSV reactivation occurred in 10% of patients after MVD for TN, including 1% of herpes zoster, and a herpes history of herpes labialis and reoperation was identified as risk factors for reactivation. HSV reactivation occurs in infected HSV patients with a history of herpes labialis, although primary infections are commonly asymptomatic.[^24] Most patients may simply be monitored, particularly if they are not immunocompromised, and the risk of developing severe disease or complications is low.[^23] Not only direct trauma to the nerve but also systemic surgical stress may activate the other side of the infected ganglion.

The incidence of HSV reactivation after various procedures on the trigeminal nerve in patients with TN is shown in Table 3. We hypothesize that the degree of procedural trauma to the trigeminal nerve plays an integral role in the development of HSV. This may be true due to the higher rate of reactivation after sectioning of the trigeminal nerve than with other procedures. However, MVD also stimulated HSV reactivation and no significant differences were observed between patients with and without postoperative facial numbness in the last follow-up, which confirmed the observation that a minimal stimulation or inapparent trauma to the trigeminal sensory root was sufficient to activate latent HSV.[^19,20]

**Table 3: Incidence of herpes simplex virus reactivation after various procedures on the trigeminal nerve in patients with trigeminal neuralgia.**

| Year | Author | Procedure | N  | Herpes labialis (n) | Other symptoms possibly caused by herpes zoster (n) | Reactivation (%) |
|------|--------|-----------|----|---------------------|-----------------------------------------------|-----------------|
| 1905 | Cushing[^10] | Removal of the Gasserian ganglion | 20 | 0                   | 2                                              | 10              |
| 1952 | Carton and Kilbourne[^8] | Sensory root section | 17 | 11                  | 5                                              | 94              |
| 1960 | Burdick et al.[^7] | MVD | 148 | 49                  | 0                                              | 33              |
| 1978 | Pazin et al.[^19] | MVD | 56  | 28                  | 0                                              | 50              |
| 1979 | Pazin et al.[^20] | MVD | 37  | 24                  | 0                                              | 65              |
| 1984 | Ho and Pazin[^11] | MVD | 55  | 22                  | 5                                              | 40              |
| 1982 | Lunsford[^6] | Glycerol injection | 27 | 8                   | 0                                              | 27              |
| 1986 | Beck et al.[^9] | Glycerol injection | 58 | 5                   | 0                                              | 9               |
| 1986 | Arias[^2] | Glycerol injection | 100 | 10                  | 0                                              | 10              |
| 1988 | Young[^25] | Glycerol injection | 162 | 61                  | 0                                              | 38              |
| 1988 | Burchiel[^6] | Glycerol injection | 60  |                     |                                                | 5               |
| 1992 | Klun[^15] | MVD | 178 |                     | ≈50                                            | ≈100            |
| 1992 | Klun[^15] | Partial sensory rhizotomy | 42 |                     |                                                |                 |
| 2008 | Oh et al.[^18] | MVD | 27  | 0                   | 1                                              | 4               |
| 2008 | Oh et al.[^18] | Gamma knife | 18 | 0                   | 1                                              | 6               |
| 2013 | Bender et al.[^4] | Glycerol injection | 470 | 37                  | 0                                              | 8               |
| 2013 | Bender et al.[^4] | Radiofrequency thermocoagulation | 287 | 10                  | 0                                              | 3               |
| 2018 | Chen et al.[^9] | MVD | 68  | 10                  | 0                                              | 15              |
| 2018 | Chen et al.[^9] | PBC | 42  | 15                  | 0                                              | 36              |
| 2019 | Berra et al.[^5] | MVD | 58  | 18                  | 0                                              | 31              |
| 2019 | Berra et al.[^5] | PBC | 34  | 12                  | 0                                              | 35              |
| 2022 | Kikuchi | MVD | 200 | 18                  | 2                                              | 10              |

MVD: Microvascular decompression, PBC: Percutaneous balloon compression
CONCLUSION

HSV reactivation occurred in 10% of patients after MVD including 1% of herpes zoster. A previous history of herpes labialis and reoperation was identified as risk factors for reactivation. A minimal stimulation or inapparent trauma to the trigeminal sensory root is sufficient to activate latent herpes virus. Symptoms were mild and cured by normal treatment without severe complications. It is important to note that cases of herpes zoster may be confused with those of HSV.

Acknowledgments

The authors are thankful to Drs. Shigeru Tani and Mikhail Chernov for their help during study and preparing of this paper for publication.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Arduino PG, Porter SR. Herpes simplex virus Type 1 infection: Overview on relevant clinico-pathological features. J Oral Pathol Med 2008;37:107-21.
2. Arias MJ. Percutaneous retrogasserian glycerol rhizotomy for trigeminal neuralgia. A prospective study of 100 cases. J Neurosurg 1986;65:32-6.
3. Beck DW, Olson JJ, Urig EJ. Percutaneous retrogasserian glycerol rhizotomy for treatment of trigeminal neuralgia. J Neurosurg 1986;65:28-31.
4. Bender MT, Pradilla G, Batra S, See AP, James C, Pardo CA, et al. Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis. J Neurosurg 2018;118:329-36.
5. Berra LV, Armocida D, Pesce A, Di Rita A, Santoro A. Herpes simplex reactivation after surgical treatment of trigeminal neuralgia: A retrospective cohort study. World Neurosurg 2019;127:e16-21.
6. Burchiel KJ. Percutaneous retrogasserian glycerol rhizolysis in the management of trigeminal neuralgia. J Neurosurg 1988;69:361-6.
7. Burdick KH, Haserick JR, Gardner WJ. Herpes simplex following decompression operations for trigeminal neuralgia. Attempts to modify by local use of hydrocortisone preparations. Arch Dermatol 1960;81:919-21.
8. Carton CA, Kilbourne ED. Activation of latent herpes simplex by trigeminal sensory-root section. N Engl J Med 1952;246:172-6.
9. Chen JN, Yu WH, Du HG, Jiang L, Dong XQ, Cao J. Prospective comparison of redo microvascular decompression and percutaneous balloon compression as primary surgery for recurrent trigeminal neuralgia. J Korean Neurosurg Soc 2018;61:747-52.
10. Cushing H. The surgical aspects of major neuralgia of the trigeminal nerve: A report of twenty cases of operation on the Gasserian ganglion with anatomic and physiologic notes on the consequences of its removal. JAMA 1905;44:1002-8.
11. Ho M, Pazin GJ, Armstrong JA, Haverkos HS, Dummer JS, Jannetta PJ. Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular decompression for trigeminal neuralgia. J Infect Dis 1984;150:867-72.
12. John AR, Canaday DH. Herpes zoster in the older adult. Infect Dis Clin North Am 2017;31:811-26.
13. Kasuya H, Tani S, Kubota Y, Yokosako S, Ohbuchi H, Arai N, et al. Characteristics and management of the offending veins in microvascular decompression surgery for trigeminal neuralgia. Neurosurg Rev 2021;44:2337-47.
14. Kennedy PG, Gershon AA. Clinical features of varicella-zoster virus infection. Viruses 2018;10:609.
15. Klun B. Microvascular decompression and partial sensory rhizotomy in the treatment of trigeminal neuralgia: Personal experience with 220 patients. Neurosurgery 1992;30:49-52.
16. Lunsford LD. Treatment of tic douloureux by percutaneous retrogasserian glycerol injection. JAMA 1982;248:449-53.
17. McLaughlin DC, Achey RL, Geertman R, Grossman J. Herpes simplex reactivation following neurosurgery: Case report and review of the literature. Neurosurg Focus 2019;47:E9.
18. Oh IH, Choi SK, Park BJ, Kim TS, Rhee BA, Lim YJ. The treatment outcome of elderly patients with idiopathic trigeminal neuralgia: Micro-vascular decompression versus gamma knife radiosurgery. J Korean Neurosurg Soc 2008;44:199-204.
19. Pazin GJ, Ho M, Jannetta PJ. Reactivation of herpes simplex virus after decompression of the trigeminal nerve root. J Infect Dis 1978;138:405-9.
20. Pazin GJ, Armstrong JA, Lam MT, Tarr GC, Jannetta PJ, Ho M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med 1979;301:225-30.
21. Rogers CL, Shetter AG, Fiedler JA, Smith KA, Han PP, Speiser BL. Gamma knife radiosurgery for trigeminal neuralgia: The initial experience of the barrow neurological institute. Int J Radiat Oncol Biol Phys 2000;47:1013-9.
22. Simms HN, Dunn LT. Herpes zoster of the trigeminal nerve following microvascular decompression. Br J Neurosurg 2006;20:423-6.
23. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001;357:1513-8.
24. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus Type 1 and Type 2 seroprevalence in the United States. JAMA 2006;296:964-73.
25. Young RF. Glycerol rhizolysis for treatment of trigeminal neuralgia. J Neurosurg 1984;60:423-6.

How to cite this article: Kikuchi A, Ishizaki S, Yokosako S, Kasuya H, Kubota Y. Clinical features of herpes simplex virus reactivation after microvascular decompression for trigeminal neuralgia: Experience of 200 patients and a literature review. Surg Neurol Int 2022;13:371.